{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"Positive ADA at baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"},{"groupId":"OG003","value":"0"}]}],"title":"Positive ADA at any time after dosing."}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Participant specimens were evaluated for the presence of ADA beginning a baseline and throughout the study. If at any time during the study, the results show evidence of ADA, they were counted as ADA positive. There was no time-to- event analysis nor by visit analysis of the data.","groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"NUMBER","populationDescription":"The ADA Evaluable Population was used for this analysis. Participants in the control arm did not receive MGC018.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks throughout the study, average duration of participation was 10 months.","title":"Number of Participants Who Develop Anti-drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"participants"}